Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: strong cost management and cash position are positive, but declining revenues, gross margins, and ongoing cash burn are concerning. The optimistic guidance and strategic partnerships offer potential upside, yet uncertainties in revenue timing and market conditions temper expectations. The Q&A session reveals cautious optimism but lacks clarity on key issues. Overall, the stock price is likely to remain neutral in the short term as positive strategic moves are counterbalanced by financial and operational challenges.
Key Financial Performance
Revenue $40.8 million, down 10% year-over-year due to a weaker market compared to last year's Q1 and elevated backlog to start 2024.
Consumables Revenue $14.5 million, down 16% year-over-year attributed to lower volumes impacted by lower Americas academia revenue and fewer large-scale clinical research projects.
Instruments Revenue $7.8 million, up 24% year-over-year driven by continued sales traction in spatial proteomics, particularly the Hyperion XTi.
Services Revenue $17.6 million, down 16% year-over-year, with lab services down 19% due to a gap in backlog and project timing.
Gross Margin 53.2%, down from 56.2% year-over-year, impacted by lower volume, lower price realization on services, and product mix.
Operating Expenses $38.6 million, down 22% year-over-year due to operationalized cost reductions totaling $90 million since the merger with SomaLogic.
Net Loss $26 million, improved by $6.2 million or 19% compared to a net loss of $32.2 million in Q1 2024.
Adjusted EBITDA Loss of $16.9 million, improved by $6.8 million or 29% compared to a loss of $23.7 million in Q1 2024.
Cash Position $261 million in cash and equivalents, with no material debt, indicating a strong balance sheet.
Cash Burn $34 million, reduced from $101 million in Q1 2024, with adjusted cash burn at $31 million, a 33% reduction year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Introduced three new offerings at AACR: single SOMAmer agents, CyTOF-XT Pro, and SomaScan 3.7K Select Asset, enhancing the proteomics portfolio.
SomaScan Offering: Announced a new SomaScan offering that pairs with the distributed NGS-based Illumina partner solution, expanding reach in translational and clinical research.
Market Positioning: Strengthened strategic foothold in proteomics with high-impact product launches and partnerships, particularly with Illumina.
International Market Engagement: International markets and biopharma engagement remain resilient, with increased traction in APAC.
Operational Efficiencies: Achieved a 22% year-over-year improvement in non-GAAP operating expenses, with a total of $90 million in annualized cost reductions since the merger with SomaLogic.
Cash Position: Ended Q1 with $261 million in cash and equivalents, no material debt, and a 33% reduction in adjusted cash burn.
Strategic Shifts: Adopted a disciplined M&A strategy and operational model, focusing on high-margin consumables and leveraging SBS for continuous improvement.
Integration of SomaLogic: Successfully integrated SomaLogic, realizing operational synergies and improving fundamentals, positioning the platform for large-scale studies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company is navigating a dynamic macro environment with persistent headwinds, including a mid-teens percentage decline in Americas academic revenue and funding uncertainties.
Tariff Impacts: New tariff measures have added complexity and disruption to global trade, particularly affecting products made in Singapore, which are now subject to a 10% tariff.
Operational Risks: The company is facing variability in revenue from consumables and lab services, attributed to project timing and funding delays in the Americas.
Cost Management: The company has implemented significant cost reductions totaling $90 million since the merger with SomaLogic, which is crucial for navigating current macroeconomic uncertainties.
Cash Flow Risks: Despite a healthy cash position of $261 million, the company is experiencing cash burn, which was $34 million in Q1 2025, though this is an improvement from the previous year.
Regulatory Issues: The geopolitical backdrop is highly volatile, which poses risks to operational stability and market conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Focus on proteomics and recent product launches, including the new SomaScan offering and partnership with Illumina to enhance translational and clinical research.
Cost Reduction: Executed an additional $10 million in cost reductions on top of $80 million operationalized in 2024, primarily focused on long-horizon R&D projects.
Integration of SomaLogic: Successfully integrated SomaLogic, realizing over $80 million in cost savings and improving operational efficiencies.
SBS Implementation: Applied Standard BioTools Business System (SBS) to streamline operations and enhance accountability across the organization.
Market Positioning: Positioned to leverage high-margin consumables and expand market share through strategic partnerships and product offerings.
Revenue Guidance: Full year 2025 revenue expected in the range of $165 million to $175 million, with a mid-teens percentage decline in Americas academic revenue.
Adjusted EBITDA Outlook: Targeting positive adjusted EBITDA by 2026.
Cash Position: Ended Q1 2025 with approximately $261 million in cash and equivalents, indicating a strong financial position.
Tariff Impact: Estimated low single-digit million dollar impact on gross margin and adjusted EBITDA due to tariffs.
Cost Management: Continued focus on cost management with a total of $90 million in annualized cost reductions since the merger.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Standard BioTools has executed an additional $10 million in cost reduction on top of the $80 million operationalized in 2024, primarily focused on long-horizon R&D projects. This is part of their strategy to streamline operations and reinforce operating leverage.
Cash Position: The company ended the first quarter with approximately $261 million in cash, cash equivalents, restricted cash, and short-term investments with no material debt.
Revenue Guidance: Standard BioTools continues to expect full year 2025 revenue in the range of $165 million to $175 million.
Tariff Impact: The gross annualized impact of new tariffs is estimated to be in the low single-digit millions of dollars, and the company plans to pass these tariffs to customers where possible.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the percentage split between first half, second half?
A:We're not being overly specific on that, but as we look at our internal funnel, we do see some larger projects that'll hit in the back half of the year.
Q:Did you see any pull forward in the first quarter, maybe? How are you seeing your overall sales funnel going forward?
A:We're encouraged by the growth in our funnel, primarily in the Hyperion XTi, but also some traction on our other instruments.
Q:Has anything changed in regards to your pipeline and the potential timing of any deals?
A:Strategic M&A is part of our founding thesis. It remains a core part of the strategy in here.
Q:Any more color on how U.S. academic progressed through 1Q and any color on how it's trended here into 2Q?
A:We've seen some delay in consumables orders. Whether those are permanent, we don't know.
Q:Can you just remind us on the commercial model for the single SOMAmers?
A:We see this as a fairly significant opportunity.
Q:Are you expecting the Illumina partnership to generate significant revenue in 2025?
A:We're cautious for ‘25, but long-term see this as a very strong value driver.
Q:Can you talk about what you're seeing within the biopharmaceutical customer set?
A:Good traction in pharma here in Q1, and have not seen a change from that as I'm sitting here today.
Q:Should we think about an improved outlook for EBITDA loss this year?
A:Yes, you will see that flow through our approach.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the percentage split between first half and second half revenue, stating they are not being overly specific. Additionally, they lacked clarity on the delay in consumables orders, indicating uncertainty about whether these delays are permanent.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACR
Americas academia
Consumables
SEC
Select
XT Pro
backdrop
backlog
biobanks
cancer
case
choice
consistency
digit million
drug
field service
financials
fundamental
gap
leverage
loss
macro
material debt
mission
momentum
others
picture
population study
position
precision
research
researcher
resource
scale
system
tariff
teen
throughput
timing
traction
volume
LAB Transcript
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Unknown5-6
The earnings call presents mixed signals: strong cost management and cash position are positive, but declining revenues, gross margins, and ongoing cash burn are concerning. The optimistic guidance and strategic partnerships offer potential upside, yet uncertainties in revenue timing and market conditions temper expectations. The Q&A session reveals cautious optimism but lacks clarity on key issues. Overall, the stock price is likely to remain neutral in the short term as positive strategic moves are counterbalanced by financial and operational challenges.
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings report highlights several negative factors: a 9% revenue decline, significant drops in instrument and lab services revenue, and decreased gross margins. Despite improved cost management and strong consumables growth, the overall financial performance is weak. The lack of a shareholder return plan and unclear management guidance further contribute to uncertainty. The Q&A session reveals limited confidence in market recovery and no specific guidance on cash burn. The positive Illumina partnership is overshadowed by broader financial challenges, leading to a likely negative stock reaction.
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed picture. While there are positive developments like cost synergies and reduced cash burn, revenue decline and reliance on major customers pose risks. The partnership with Illumina and growth in consumables are positives, but weak instrument sales and cautious guidance for China offset these gains. The Q&A highlights management's cautious stance and lack of specific guidance, which could concern investors. Given these mixed signals, the stock price is likely to remain neutral in the short term.
Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong partnership with Illumina, strategic capital allocation, and cost reductions are positive. However, declining revenues, gross margins, and CFO departure pose risks. The Q&A reveals management's limited transparency and reliance on a few large accounts, adding uncertainty. The share repurchase program offers some support, but overall, the mixed signals and lack of specific guidance adjustments suggest a neutral stock price movement in the short term.
LAB Slides
LAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
